FINRA Announces Approval for Corporate Name Change From "China Infrastructure Construction Corp." to "Cannabis Bioscience International Holdings" And Ticker Symbol Change from "CHNC" to "CBIH".
- None.
- None.
Houston, TX -- August 21, 2023 -- InvestorsHub NewsWire -- Cannabis Bioscience International Holdings (the "Company") a diversified medical and educational company with a particular focus on traditional clinical trials and cannabinoids research, is excited to announce that FINRA (Financial Industry Regulatory Authority, Inc.) has approved the corporate name change from "China Infrastructure Construction Corp." to "Cannabis Bioscience International Holdings" as well as its ticker symbol change from "CHNC" to "CBIH".
CBIH's treasurer Henry Levinski, said "Adopting to a new stock ticker symbol is a reflection of the progress we have made in our strategy of reinventing/rebranding our company since our merger. This further establishes CBIH as a diversified Houston-based company with a clear identity, instead of the two-fold confusion that the former generated in name and ticker symbol. In the next weeks, brand identity that reflects this change will be announced."
No action is required by the Company's current shareholders as a result of this change, and it has been reported that from August 17 to today the change in the ticker symbol should have been made effective on the different broker's platforms.
For more information contact us at:
info@pharmacologyuniversity.
817/528-2475 for English
214/733-0868 for Spanish
About Cannabis Bioscience International Holdings.
The company is dedicated to providing services in all therapeutic areas of clinical research through one of our products: Alpha Research Institute, LLC. a Houston-based Research Unit that offers phase I to phase IV Clinical Research Studies. The Company also operates an international learning platform that provides knowledge about cannabinoids' medical benefits: Pharmacology University. Directors and executive staff of CBIH such as chemists, biologists and doctors have spent more than 15 years researching medical cannabis uses and the creation of formulations that will aid in the recovery and healing adjuvant of various pathologies/illnesses such as cancer, chronic pain, PTSD, etc., as a result, we have also published ebooks, audiobooks, videos, and magazines that are available to the general public on various platforms around the globe. Cannabis Bioscience International Holdings will unite both business models, clinical studies, and cannabinoid education to position itself with a sustainable competitive advantage as the global number one provider of cannabis medical formulations and education.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
View the original version - https://ih.advfn.com/stock-market/USOTC/CBIH/stock-news/91862615/finra-announces-approval-for-corporate-name-change
